vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and AMERISAFE INC (AMSF). Click either name above to swap in a different company.
AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $44.9M, roughly 1.8× AbCellera Biologics Inc.). AMERISAFE INC runs the higher net margin — 10.2% vs -19.9%, a 30.1% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 10.3%). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 2.8%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.
ABCL vs AMSF — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $80.1M |
| Net Profit | $-8.9M | $8.1M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | — |
| Net Margin | -19.9% | 10.2% |
| Revenue YoY | 788.4% | 10.3% |
| Net Profit YoY | 73.9% | -9.0% |
| EPS (diluted) | $-0.03 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $80.1M | ||
| Q4 25 | $44.9M | $81.6M | ||
| Q3 25 | $9.0M | $82.0M | ||
| Q2 25 | $17.1M | $81.1M | ||
| Q1 25 | $4.2M | $72.6M | ||
| Q4 24 | $5.0M | $74.0M | ||
| Q3 24 | $6.5M | $78.7M | ||
| Q2 24 | $7.3M | $75.8M |
| Q1 26 | — | $8.1M | ||
| Q4 25 | $-8.9M | $10.4M | ||
| Q3 25 | $-57.1M | $13.8M | ||
| Q2 25 | $-34.7M | $14.0M | ||
| Q1 25 | $-45.6M | $8.9M | ||
| Q4 24 | — | $13.2M | ||
| Q3 24 | $-51.1M | $14.3M | ||
| Q2 24 | $-36.9M | $11.0M |
| Q1 26 | — | — | ||
| Q4 25 | -63.7% | 15.6% | ||
| Q3 25 | -851.8% | 21.3% | ||
| Q2 25 | -290.2% | 21.5% | ||
| Q1 25 | -1479.6% | 15.5% | ||
| Q4 24 | — | 22.7% | ||
| Q3 24 | -1439.4% | 22.6% | ||
| Q2 24 | -1276.2% | 18.1% |
| Q1 26 | — | 10.2% | ||
| Q4 25 | -19.9% | 12.8% | ||
| Q3 25 | -637.8% | 16.9% | ||
| Q2 25 | -203.3% | 17.2% | ||
| Q1 25 | -1077.2% | 12.3% | ||
| Q4 24 | — | 17.8% | ||
| Q3 24 | -785.4% | 18.2% | ||
| Q2 24 | -504.3% | 14.5% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | $-0.03 | $0.55 | ||
| Q3 25 | $-0.19 | $0.72 | ||
| Q2 25 | $-0.12 | $0.73 | ||
| Q1 25 | $-0.15 | $0.47 | ||
| Q4 24 | — | $0.69 | ||
| Q3 24 | $-0.17 | $0.75 | ||
| Q2 24 | $-0.13 | $0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | $34.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $246.6M |
| Total Assets | $1.4B | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $34.2M | ||
| Q4 25 | $128.5M | $61.9M | ||
| Q3 25 | $83.2M | $54.7M | ||
| Q2 25 | $92.4M | $48.5M | ||
| Q1 25 | $159.3M | $44.8M | ||
| Q4 24 | $156.3M | $44.1M | ||
| Q3 24 | $126.6M | $63.7M | ||
| Q2 24 | $148.3M | $30.6M |
| Q1 26 | — | $246.6M | ||
| Q4 25 | $966.9M | $251.6M | ||
| Q3 25 | $964.0M | $274.8M | ||
| Q2 25 | $1.0B | $265.6M | ||
| Q1 25 | $1.0B | $260.8M | ||
| Q4 24 | $1.1B | $257.3M | ||
| Q3 24 | $1.1B | $314.4M | ||
| Q2 24 | $1.1B | $301.0M |
| Q1 26 | — | — | ||
| Q4 25 | $1.4B | $1.1B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.4B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.4B | $1.2B | ||
| Q3 24 | $1.4B | $1.3B | ||
| Q2 24 | $1.4B | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | — |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-34.7M | $11.1M | ||
| Q3 25 | $-52.6M | $10.7M | ||
| Q2 25 | $-32.4M | $-8.4M | ||
| Q1 25 | $-11.6M | $-1.8M | ||
| Q4 24 | $-108.6M | $24.2M | ||
| Q3 24 | $-28.9M | $8.4M | ||
| Q2 24 | $-30.0M | $-2.6M |
| Q1 26 | — | — | ||
| Q4 25 | $-44.6M | $8.9M | ||
| Q3 25 | $-61.5M | $9.8M | ||
| Q2 25 | $-45.8M | $-9.5M | ||
| Q1 25 | $-22.2M | $-1.8M | ||
| Q4 24 | $-187.0M | $23.4M | ||
| Q3 24 | $-47.4M | $8.4M | ||
| Q2 24 | $-50.1M | $-2.6M |
| Q1 26 | — | — | ||
| Q4 25 | -99.4% | 10.9% | ||
| Q3 25 | -687.0% | 11.9% | ||
| Q2 25 | -267.9% | -11.7% | ||
| Q1 25 | -524.0% | -2.5% | ||
| Q4 24 | -3702.8% | 31.5% | ||
| Q3 24 | -728.4% | 10.7% | ||
| Q2 24 | -683.8% | -3.5% |
| Q1 26 | — | — | ||
| Q4 25 | 21.9% | 2.6% | ||
| Q3 25 | 99.7% | 1.1% | ||
| Q2 25 | 78.2% | 1.3% | ||
| Q1 25 | 251.1% | 0.0% | ||
| Q4 24 | 1552.7% | 1.1% | ||
| Q3 24 | 284.6% | 0.0% | ||
| Q2 24 | 274.6% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.06× | ||
| Q3 25 | — | 0.77× | ||
| Q2 25 | — | -0.61× | ||
| Q1 25 | — | -0.20× | ||
| Q4 24 | — | 1.83× | ||
| Q3 24 | — | 0.59× | ||
| Q2 24 | — | -0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
